Blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse of B-ALL in children and adolescents

CANDOR: Triple drug combo delays disease progression in stubborn multiple myeloma

Daratumuab, carfilzomib and dexamethasone increases survival in patients with relapsed/refractory multiple myeloma

Blinatumomab demonstrates superior efficacy compared to chemotherapy in children and young adults with relapsed B-ALL

Multiple myeloma highlights from ASH 2019

Carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma

Novel multi-antigen targeted CAR-NK cell for the treatment of B cell malignancies

Multiple myeloma: Anti-BCMA BiTE AMG 701 shows preclinical promise

Bispecific CAR T-cell therapy as treatment for hard to treat multiple myeloma

Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients

CAR T-cell therapy in hard-to-treat multiple myeloma produces sustained remissions

Multiple myeloma patients treated with BCMA-directed CAR T-cell therapy have high response rate